{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:10:29Z","timestamp":1780945829643,"version":"3.54.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T00:00:00Z","timestamp":1711065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017577","name":"Basic Public Welfare Research Program of Zhejiang Province","doi-asserted-by":"publisher","award":["LGD20H310002"],"award-info":[{"award-number":["LGD20H310002"]}],"id":[{"id":"10.13039\/501100017577","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81903584"],"award-info":[{"award-number":["81903584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.seizure.2024.03.009","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T05:34:15Z","timestamp":1711085655000},"page":"253-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7976-297X","authenticated-orcid":false,"given":"Zhimin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowen","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-0207","authenticated-orcid":false,"given":"Gang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.seizure.2024.03.009_bib0001","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1001\/jama.2022.3880","article-title":"Antiseizure medications for adults with epilepsy: a review","volume":"327","author":"Kanner","year":"2022","journal-title":"JAMA"},{"issue":"10172","key":"10.1016\/j.seizure.2024.03.009_bib0002","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.seizure.2024.03.009_bib0003","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2024.03.009_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2006.02.022","article-title":"Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein","volume":"536","author":"Gillard","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"10.1016\/j.seizure.2024.03.009_bib0005","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1528-1167.2006.01132.x","article-title":"Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission","volume":"48","author":"Yang","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2024.03.009_bib0006","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/sj.bjp.0704766","article-title":"The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents","volume":"136","author":"Rigo","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2024.03.009_bib0007","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1006\/phrs.2000.0689","article-title":"Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs","volume":"42","author":"Margineanu","year":"2000","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.seizure.2024.03.009_bib0008","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/FTD.0000000000000291","article-title":"Population pharmacokinetic modeling of Levetiracetam in pediatric and adult patients with epilepsy by using routinely monitored data","volume":"38","author":"Ito","year":"2016","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2024.03.009_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review","volume":"118","author":"Steinhoff","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2024.03.009_bib0010","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/ana.10473","article-title":"A novel mechanism underlying drug resistance in chronic epilepsy","volume":"53","author":"Remy","year":"2003","journal-title":"Ann Neurol"},{"issue":"38","key":"10.1016\/j.seizure.2024.03.009_bib0011","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.2174\/1381612822666160810150416","article-title":"ABC transporters and drug resistance in patients with epilepsy","volume":"22","author":"Feldmann","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"5","key":"10.1016\/j.seizure.2024.03.009_bib0012","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1528-1167.2007.01302.x","article-title":"ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy","volume":"48","author":"Lazarowski","year":"2007","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2024.03.009_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral","year":"2020","journal-title":"Disease-a-Month"},{"issue":"6","key":"10.1016\/j.seizure.2024.03.009_bib0014","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1515\/CCLM.2010.151","article-title":"Rhabdomyolysis: historical background, clinical, diagnostic and therapeutic features","volume":"48","author":"Cervellin","year":"2010","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"10.1016\/j.seizure.2024.03.009_bib0015","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.coph.2012.04.002","article-title":"Drug induced rhabdomyolysis","volume":"12","author":"Hohenegger","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0016","first-page":"58","article-title":"Rhabdomyolysis: pathogenesis, diagnosis, and treatment","volume":"15","author":"Torres","year":"2015","journal-title":"Ochsner J"},{"issue":"4","key":"10.1016\/j.seizure.2024.03.009_bib0017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.64719\/pb.4421","article-title":"Myotoxicity induced by antiepileptic drugs: could be a rare but serious adverse event?","volume":"51","author":"Siniscalchi","year":"2021","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.seizure.2024.03.009_bib0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ebcr.2014.08.001","article-title":"A case of rhabdomyolysis in which levetiracetam was suspected as the cause","volume":"2","author":"Akiyama","year":"2014","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.seizure.2024.03.009_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1197470","article-title":"Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study","volume":"14","author":"Deng","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.seizure.2024.03.009_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1254\/fpj.152.275","article-title":"Function of ssynaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy","volume":"152","author":"Tokudome","year":"2018","journal-title":"Nihon Yakurigaku Zasshi"},{"issue":"20","key":"10.1016\/j.seizure.2024.03.009_bib0021","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1242\/dev.053348","article-title":"Retrograde influence of muscle fibers on their innervation revealed by a novel marker for slow motoneurons","volume":"137","author":"Chakkalakal","year":"2010","journal-title":"Development"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0022","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/MJT.0b013e3181ff7c79","article-title":"Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations","volume":"20","author":"Kar","year":"2013","journal-title":"Am J Ther"},{"issue":"38","key":"10.1016\/j.seizure.2024.03.009_bib0023","doi-asserted-by":"crossref","first-page":"13879","DOI":"10.3748\/wjg.v20.i38.13879","article-title":"Treatment of severe acute pancreatitis and its complications","volume":"20","author":"Zerem","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.seizure.2024.03.009_bib0024","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000335627","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Harr","year":"2012","journal-title":"Chem Immunol Allergy"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0025","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1001\/2013.jamadermatol.266","article-title":"Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens-Johnson syndrome in 2 cases","volume":"149","author":"Duong","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.seizure.2024.03.009_bib0026","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1097\/MJT.0000000000000105","article-title":"Rare red rashes: a case report of Levetiracetam-induced cutaneous reaction and review of the literature","volume":"23","author":"Jones","year":"2016","journal-title":"Am J Ther"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0027","doi-asserted-by":"crossref","first-page":"12","DOI":"10.5070\/D39346H1K6","article-title":"A case of erythema multiforme developing after levetiracetam therapy","volume":"19","author":"Yesilova","year":"2013","journal-title":"Dermatol Online J"},{"issue":"10","key":"10.1016\/j.seizure.2024.03.009_bib0028","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.seizure.2012.09.005","article-title":"Stevens-Johnson syndrome induced by levetiracetam","volume":"21","author":"Zou","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/1346-8138.12674","article-title":"Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"42","author":"Abe","year":"2015","journal-title":"J Dermatol"},{"issue":"5","key":"10.1016\/j.seizure.2024.03.009_bib0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1365-2125.2010.03764.x","article-title":"Delayed drug hypersensitivity: models of T-cell stimulation","volume":"71","author":"Adam","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0031","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/0019-5154.177777","article-title":"Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome","volume":"61","author":"Dar","year":"2016","journal-title":"Indian J Dermatol"},{"issue":"4","key":"10.1016\/j.seizure.2024.03.009_bib0032","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0033","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1665-2681(19)31663-1","article-title":"Severe acute hepatitis in the dress syndrome: report of two cases","volume":"9","author":"Lens","year":"2010","journal-title":"Ann Hepatol"},{"issue":"7\u20138","key":"10.1016\/j.seizure.2024.03.009_bib0034","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1345\/aph.1R084","article-title":"Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome","volume":"46","author":"G\u00f3mez-Zorrilla","year":"2012","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0035","first-page":"e22359","article-title":"Drug reaction with eosinophilia and systemic symptoms syndrome in a patient taking lamotrigine: a case report based literature review","volume":"14","author":"Khan","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0036","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/jdv.12346","article-title":"Dress syndrome induced by levetiracetam","volume":"29","author":"Eleni","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.seizure.2024.03.009_bib0037","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1346-8138.2010.01176.x","article-title":"New aspects of drug-induced hypersensitivity syndrome","volume":"38","author":"Tohyama","year":"2011","journal-title":"J Dermatol"},{"issue":"11","key":"10.1016\/j.seizure.2024.03.009_bib0038","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med"},{"issue":"13","key":"10.1016\/j.seizure.2024.03.009_bib0039","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1212\/WNL.0000000000006240","article-title":"Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy","volume":"91","author":"Voinescu","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/epi.17800","article-title":"Antiepileptic treatment with levetiracetam during the first trimester and pregnancy outcome: an observational study","volume":"65","author":"Hoeltzenbein","year":"2024","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2024.03.009_bib0041","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0000000000001840","article-title":"Antiepileptic drugs and intrauterine death: a prospective observational study from EURAP","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.03.009_bib0042","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.eplepsyres.2018.07.016","article-title":"Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India","volume":"146","author":"Trivedi","year":"2018","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0043","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.yebeh.2013.06.026","article-title":"Antiepileptic drug clearance and seizure frequency during pregnancy in women with epilepsy","volume":"29","author":"Reisinger","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0044","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2024.03.009_bib0045","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes. Commission on classification and terminology of the international league against epilepsy","volume":"30","year":"1989","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0046","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4103\/ijp.IJP_692_17","article-title":"Levetiracetam use during pregnancy in women with epilepsy: preliminary observations from a tertiary care center in Northern India","volume":"50","author":"Bansal","year":"2018","journal-title":"India J Pharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0047","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/pbc.24371","article-title":"Drug-drug interaction between methotrexate and levetiracetam in a child treated for acute lymphoblastic leukemia","volume":"60","author":"Parentelli","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0048","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1060028013511951","article-title":"Drug-drug interaction between methotrexate and Levetiracetam resulting in delayed methotrexate elimination","volume":"48","author":"Bain","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.seizure.2024.03.009_bib0049","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1177\/1060028016661572","article-title":"Methotrexate elimination when coadministered with Levetiracetam","volume":"50","author":"Reeves","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0050","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7326\/L19-0712","article-title":"Rivaroxaban plasma levels and Levetiracetam: a case report","volume":"173","author":"Paciullo","year":"2020","journal-title":"Ann Intern Med"},{"issue":"10225","key":"10.1016\/j.seizure.2024.03.009_bib0051","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(19)33064-8","article-title":"Epilepsy in older people","volume":"395","author":"Sen","year":"2020","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.seizure.2024.03.009_bib0052","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/eurheartj\/ehy780","article-title":"Drug-drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants","volume":"40","author":"Mathy","year":"2019","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.seizure.2024.03.009_bib0053","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1528-1157.1997.tb01480.x","article-title":"Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy","volume":"38","author":"Samr\u00e9n","year":"1997","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.seizure.2024.03.009_bib0054","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.seizure.2024.03.009_bib0055","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/WNL.0b013e31827f0874","article-title":"Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers","volume":"80","author":"Mawhinney","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2024.03.009_bib0056","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.seizure.2018.12.006","article-title":"Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register","volume":"65","author":"Vajda","year":"2019","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2024.03.009_bib0057","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0058","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2024.03.009_bib0059","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40801-016-0078-1","article-title":"The risk of specific congenital anomalies in relation to newer antiepileptic drugs: a literature review","volume":"3","author":"de Jong","year":"2016","journal-title":"Drug Real World Outcome"},{"issue":"11","key":"10.1016\/j.seizure.2024.03.009_bib0060","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","volume":"11","author":"Weston","year":"2016","journal-title":"Cochr Datab Syst Rev"},{"key":"10.1016\/j.seizure.2024.03.009_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109453","article-title":"Dosage, time, and polytherapy dependent effects of different levetiracetam regimens on cognitive function","volume":"148","author":"Perkins","year":"2023","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.seizure.2024.03.009_bib0062","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1528-1167.2005.54804.x","article-title":"Levetiracetam concentrations in serum and in breast milk at birth and during lactation","volume":"46","author":"Johannessen","year":"2005","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112400075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913112400075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:10:25Z","timestamp":1762362625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913112400075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":62,"alternative-id":["S105913112400075X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2024.03.009","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world safety of Levetiracetam: Mining and analysis of its adverse drug reactions based on FAERS database","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2024.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}